PDS Biotechnology CSO's 299,567 options await approval
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PDS Biotechnology Corp reported an employee stock option award covering 299,567 common shares to its Chief Scientific Officer on November 16, 2026, subject to stockholder approval of its 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option has a $0.9241 exercise price and is not exercisable until approval. If approved, it vests in equal monthly installments over four years beginning December 16, 2026, subject to continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) F1 | 299,567 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, the shares subject to the option shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation.
Key Figures
Key Terms
Nasdaq Marketplace Rule 5635(c) regulatory
vesting technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does the PDSB Chief Scientific Officer option expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.